Methods and compositions for treating recurrent cancer

1. A method of treating a recurrent ovarian, peritoneal, or fallopian tube cancer in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising a taxane and a carrier protein, wherein the individual has received a prior chemotherapy and has a treatment free interval for more than about three months prior to the initiation of the treatment, wherein the nanoparticle composition is not administered in conjunction with a platinum-based agent, and wherein the composition comprising nanoparticles comprising a taxane and a carrier protein is administered at a single dose of about 5 mg/m 2 to about 400 mg/m 2 every three weeks.

2. The method of claim 1 , wherein the recurrent ovarian, peritoneal, or fallopian cancer is platinum-sensitive.

3. The method of claim 1 , wherein the individual has received a prior platinum-based chemotherapy and has a treatment free interval of more than about 12 months since the completion of the platinum-based chemotherapy.

4. The method of claim 1 , wherein the composition comprising nanoparticles comprising a taxane and a carrier protein is administered alone.

5. The method of claim 1 , wherein the taxane is paclitaxel.

6. The method of claim 1 , wherein the carrier protein is albumin.

7. The method of claim 1 , wherein the nanoparticles in the composition have an average or mean diameter of no greater than about 200 nm.

8. The method of claim 7 , wherein the composition comprising nanoparticles comprising a taxane and a carrier protein is Nab-paclitaxel.

9. The method of claim 1 , wherein the individual has received a prior chemotherapy and has a treatment free interval for more than about 6 months prior to the initiation of the treatment.

10. The method of claim 1 , wherein the individual does not show a symptom of hypersensitivity prior to the initiation of the treatment.

11. The method of claim 1 , wherein the individual does not show a symptom resulting from the recurrent cancer upon completion of the treatment.

12. The method of claim 1 , wherein the individual has a reduced CA-125 level upon completion of the treatment.

13. The method of claim 1 , wherein the nanoparticles comprise the taxane coated with a coating comprising the carrier protein.

14. The method of claim 13 , wherein the taxane is paclitaxel.

15. The method of claim 13 , wherein the carrier protein is albumin.

16. The method of claim 1 , wherein the nanoparticles composition is administered intravenously.

17. The method of claim 1 , wherein the nanoparticle composition is administered intraperitoneally.

18. The method of claim 7 , wherein the nanoparticles comprise the taxane coated with a coating comprising the carrier protein.

19. The method of claim 18 , wherein the taxane is paclitaxel.

20. The method of claim 18 , wherein the carrier protein is albumin.

21. The method of claim 19 , wherein the carrier protein is albumin.

22. The method of claim 7 , wherein the nanoparticles composition is administered intravenously.

23. The method of claim 7 , wherein the nanoparticle composition is administered intraperitoneally.

24. The method of claim 8 , wherein the nanoparticles composition is administered intravenously.

25. The method of claim 8 , wherein the nanoparticle composition is administered intraperitoneally.

26. The method of claim 21 , wherein the nanoparticles composition is administered intravenously.

27. The method of claim 21 , wherein the nanoparticle composition is administered intraperitoneally.

28. The method of claim 1 , wherein the composition comprising nanoparticles comprising a taxane and a carrier protein is administered at a single dose of about 180 mg/m 2 to about 300 mg/m 2 every three weeks.

29. The method of claim 1 , wherein the composition comprising nanoparticles comprising a taxane and a carrier protein is administered at a single dose of about 260 mg/m 2 every three weeks.